

Ian A Wilson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5491764/publications.pdf>

Version: 2024-02-01

353
papers

57,976
citations

867

120
h-index

1631

221
g-index

406
all docs

406
docs citations

406
times ranked

41549
citing authors

#	ARTICLE	IF	CITATIONS
1	Broad neutralization coverage of HIV by multiple highly potent antibodies. <i>Nature</i> , 2011, 477, 466-470.	13.7	1,397
2	A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. <i>Science</i> , 2020, 368, 630-633.	6.0	1,379
3	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. <i>Science</i> , 2020, 369, 956-963.	6.0	1,287
4	Antibody Recognition of a Highly Conserved Influenza Virus Epitope. <i>Science</i> , 2009, 324, 246-251.	6.0	1,220
5	New World Bats Harbor Diverse Influenza A Viruses. <i>PLoS Pathogens</i> , 2013, 9, e1003657.	2.1	1,050
6	Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 17033-17038.	3.3	1,039
7	Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design. <i>Science</i> , 2001, 293, 1155-1159.	6.0	870
8	Structure and Receptor Specificity of the Hemagglutinin from an H5N1 Influenza Virus. <i>Science</i> , 2006, 312, 404-410.	6.0	865
9	A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies. <i>PLoS Pathogens</i> , 2013, 9, e1003618.	2.1	835
10	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	13.7	794
11	Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer. <i>Science</i> , 2013, 342, 1477-1483.	6.0	793
12	A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses. <i>Science</i> , 2011, 333, 843-850.	6.0	772
13	Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition. <i>Science</i> , 2003, 300, 2065-2071.	6.0	736
14	HIV vaccine design and the neutralizing antibody problem. <i>Nature Immunology</i> , 2004, 5, 233-236.	7.0	721
15	Highly Conserved Protective Epitopes on Influenza B Viruses. <i>Science</i> , 2012, 337, 1343-1348.	6.0	705
16	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	13.7	681
17	Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. <i>Science</i> , 2013, 340, 711-716.	6.0	680
18	The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of 1±1â†’2 Mannose Residues on the Outer Face of gp120. <i>Journal of Virology</i> , 2002, 76, 7306-7321.	1.5	664

#	ARTICLE	IF	CITATIONS
19	Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer. <i>Science</i> , 2013, 342, 1484-1490.	6.0	662
20	A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield. <i>Science</i> , 2011, 334, 1097-1103.	6.0	644
21	Structural Basis of Plasticity in T Cell Receptor Recognition of a Self Peptide-MHC Antigen. <i>Science</i> , 1998, 279, 1166-1172.	6.0	641
22	A structural analysis of M protein in coronavirus assembly and morphology. <i>Journal of Structural Biology</i> , 2011, 174, 11-22.	1.3	625
23	Glycan Microarray Analysis of the Hemagglutinins from Modern and Pandemic Influenza Viruses Reveals Different Receptor Specificities. <i>Journal of Molecular Biology</i> , 2006, 355, 1143-1155.	2.0	570
24	Crystal Structure of Human Toll-Like Receptor 3 (TLR3) Ectodomain. <i>Science</i> , 2005, 309, 581-585.	6.0	545
25	Structural basis of a shared antibody response to SARS-CoV-2. <i>Science</i> , 2020, 369, 1119-1123.	6.0	536
26	Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin. <i>Science</i> , 2011, 332, 816-821.	6.0	527
27	Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. <i>Science</i> , 2010, 328, 357-360.	6.0	521
28	Antibody-antigen interactions: new structures and new conformational changes. <i>Current Opinion in Structural Biology</i> , 1994, 4, 857-867.	2.6	505
29	STRUCTURAL BASIS OF T CELL RECOGNITION. <i>Annual Review of Immunology</i> , 1999, 17, 369-397.	9.5	488
30	HIV-1 neutralizing antibodies induced by native-like envelope trimers. <i>Science</i> , 2015, 349, aac4223.	6.0	482
31	A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. <i>Science</i> , 2015, 349, 1301-1306.	6.0	480
32	Structural Basis of TLR5-Flagellin Recognition and Signaling. <i>Science</i> , 2012, 335, 859-864.	6.0	454
33	Structure of the Uncleaved Human H1 Hemagglutinin from the Extinct 1918 Influenza Virus. <i>Science</i> , 2004, 303, 1866-1870.	6.0	440
34	Cross-neutralization of influenza A viruses mediated by a single antibody loop. <i>Nature</i> , 2012, 489, 526-532.	13.7	434
35	A Dynamic Knockout Reveals That Conformational Fluctuations Influence the Chemical Step of Enzyme Catalysis. <i>Science</i> , 2011, 332, 234-238.	6.0	414
36	Broadly Neutralizing Anti-HIV Antibody 4E10 Recognizes a Helical Conformation of a Highly Conserved Fusion-Associated Motif in gp41. <i>Immunity</i> , 2005, 22, 163-173.	6.6	410

#	ARTICLE	IF	CITATIONS
37	Structural genomics of the <i>Thermotoga maritima</i> proteome implemented in a high-throughput structure determination pipeline. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11664-11669.	3.3	397
38	Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses. <i>Science</i> , 2012, 337, 183-186.	6.0	394
39	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. <i>Science Advances</i> , 2019, 5, eaav4580.	4.7	393
40	Exploitation of glycosylation in enveloped virus pathobiology. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 1480-1497.	1.1	383
41	HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. <i>Science</i> , 2016, 351, 1458-1463.	6.0	382
42	Hepatitis C Virus E2 Envelope Glycoprotein Core Structure. <i>Science</i> , 2013, 342, 1090-1094.	6.0	374
43	A Single Amino Acid Substitution in 1918 Influenza Virus Hemagglutinin Changes Receptor Binding Specificity. <i>Journal of Virology</i> , 2005, 79, 11533-11536.	1.5	356
44	Massively parallel de novo protein design for targeted therapeutics. <i>Nature</i> , 2017, 550, 74-79.	13.7	354
45	Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. <i>Cell Reports</i> , 2020, 31, 107725.	2.9	353
46	A Blueprint for HIV Vaccine Discovery. <i>Cell Host and Microbe</i> , 2012, 12, 396-407.	5.1	348
47	Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. <i>Nature Biotechnology</i> , 2012, 30, 543-548.	9.4	342
48	Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. <i>Immunity</i> , 2014, 40, 657-668.	6.6	342
49	Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes. <i>Cell</i> , 2015, 163, 1702-1715.	13.5	341
50	Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 206-214.	3.3	340
51	HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. <i>Immunity</i> , 2016, 45, 483-496.	6.6	335
52	Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17624-17629.	3.3	324
53	Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers. <i>Immunity</i> , 2014, 40, 669-680.	6.6	323
54	Glycan microarray technologies: tools to survey host specificity of influenza viruses. <i>Nature Reviews Microbiology</i> , 2006, 4, 857-864.	13.6	319

#	ARTICLE	IF	CITATIONS
55	Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 796-803.	3.6	314
56	Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	309
57	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 818-823.	6.0	309
58	A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. <i>Cell</i> , 2020, 183, 1058-1069.e19.	13.5	305
59	Vulnerabilities in coronavirus glycan shields despite extensive glycosylation. <i>Nature Communications</i> , 2020, 11, 2688.	5.8	304
60	Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. <i>Science</i> , 2021, 371, .	6.0	304
61	Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 13372-13377.	3.3	291
62	Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. <i>Immunity</i> , 2017, 46, 1073-1088.e6.	6.6	286
63	Crystal Structure of a Shark Single-Domain Antibody V Region in Complex with Lysozyme. <i>Science</i> , 2004, 305, 1770-1773.	6.0	282
64	Antibody-antigen interactions. <i>Current Opinion in Structural Biology</i> , 1993, 3, 113-118.	2.6	279
65	Antibody vs. HIV in a clash of evolutionary titans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14943-14948.	3.3	268
66	Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans. <i>PLoS Pathogens</i> , 2013, 9, e1003342.	2.1	267
67	The HIV-1 envelope glycoprotein structure: nailing down a moving target. <i>Immunological Reviews</i> , 2017, 275, 21-32.	2.8	251
68	Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. <i>Cell Reports</i> , 2016, 14, 2695-2706.	2.9	250
69	A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B <i>env</i> Gene. <i>Journal of Virology</i> , 2015, 89, 3380-3395.	1.5	247
70	Structural Characterization of the 1918 Influenza Virus H1N1 Neuraminidase. <i>Journal of Virology</i> , 2008, 82, 10493-10501.	1.5	241
71	Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. <i>Journal of Virology</i> , 2003, 77, 642-658.	1.5	237
72	Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 4351-4356.	3.3	236

#	ARTICLE	IF	CITATIONS
73	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. <i>Cell</i> , 2016, 166, 1459-1470.e11.	13.5	230
74	Antibody Elbow Angles are Influenced by their Light Chain Class. <i>Journal of Molecular Biology</i> , 2006, 357, 1566-1574.	2.0	229
75	Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2788-2793.	3.3	225
76	Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. <i>Nature</i> , 2017, 547, 360-363.	13.7	217
77	Major antigen-induced domain rearrangements in an antibody. <i>Structure</i> , 1993, 1, 83-93.	1.6	216
78	Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer-Elicited Neutralizing Antibodies. <i>Cell Reports</i> , 2016, 16, 2327-2338.	2.9	216
79	A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β^2 -Hairpin Structure. <i>Immunity</i> , 2017, 46, 690-702.	6.6	216
80	Arylfluorosulfates Inactivate Intracellular Lipid Binding Protein(s) through Chemoselective SuFEx Reaction with a Binding Site Tyr Residue. <i>Journal of the American Chemical Society</i> , 2016, 138, 7353-7364.	6.6	212
81	“Inverse Drug Discovery” Strategy To Identify Proteins That Are Targeted by Latent Electrophiles As Exemplified by Aryl Fluorosulfates. <i>Journal of the American Chemical Society</i> , 2018, 140, 200-210.	6.6	206
82	Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans. <i>Immunity</i> , 2015, 43, 1053-1063.	6.6	200
83	Global Efforts in Structural Genomics. <i>Science</i> , 2001, 294, 89-92.	6.0	195
84	Recent Avian H5N1 Viruses Exhibit Increased Propensity for Acquiring Human Receptor Specificity. <i>Journal of Molecular Biology</i> , 2008, 381, 1382-1394.	2.0	192
85	Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 18256-18261.	3.3	188
86	A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. <i>PLoS Pathogens</i> , 2017, 13, e1006682.	2.1	188
87	A common solution to group 2 influenza virus neutralization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 445-450.	3.3	187
88	Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. <i>Immunity</i> , 2020, 53, 1272-1280.e5.	6.6	185
89	A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. <i>Nature Medicine</i> , 2018, 24, 401-407.	15.2	183
90	Reshaping Antibody Diversity. <i>Cell</i> , 2013, 153, 1379-1393.	13.5	179

#	ARTICLE	IF	CITATIONS
91	A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. <i>Cell</i> , 2019, 177, 1136-1152.e18.	13.5	177
92	Receptor mimicry by antibody F045â€“092 facilitates universal binding to the H3 subtype of influenza virus. <i>Nature Communications</i> , 2014, 5, 3614.	5.8	175
93	Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. <i>Immunity</i> , 2018, 49, 288-300.e8.	6.6	175
94	A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses. <i>Science</i> , 2019, 366, .	6.0	172
95	Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization. <i>Cell Reports</i> , 2017, 20, 1805-1817.	2.9	171
96	Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. <i>Science</i> , 2018, 362, 598-602.	6.0	170
97	Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 192-203.	1.0	165
98	Design of protein-binding proteins from the target structure alone. <i>Nature</i> , 2022, 605, 551-560.	13.7	164
99	Antigen Recognition by Variable Lymphocyte Receptors. <i>Science</i> , 2008, 321, 1834-1837.	6.0	163
100	Recent H3N2 Viruses Have Evolved Specificity for Extended, Branched Human-type Receptors, Conferring Potential for Increased Avidity. <i>Cell Host and Microbe</i> , 2017, 21, 23-34.	5.1	163
101	Broadly protective human antibodies that target the active site of influenza virus neuraminidase. <i>Science</i> , 2019, 366, 499-504.	6.0	162
102	Structural Evolution of Glycan Recognition by a Family of Potent HIV Antibodies. <i>Cell</i> , 2014, 159, 69-79.	13.5	161
103	Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV. <i>Science Translational Medicine</i> , 2014, 6, 236ra63.	5.8	160
104	Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17040-17045.	3.3	159
105	Antibody responses to viral infections: a structural perspective across three different enveloped viruses. <i>Nature Microbiology</i> , 2019, 4, 734-747.	5.9	158
106	Structural Characterization of the Hemagglutinin Receptor Specificity from the 2009 H1N1 Influenza Pandemic. <i>Journal of Virology</i> , 2012, 86, 982-990.	1.5	155
107	Three-dimensional Structure of an Anti-steroid Fabâ€² and Progesterone-Fabâ€² Complex. <i>Journal of Molecular Biology</i> , 1993, 231, 103-118.	2.0	154
108	Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. <i>Nature</i> , 2017, 548, 108-111.	13.7	154

#	ARTICLE	IF	CITATIONS
109	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	6.6	153
110	An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. <i>Cell Reports</i> , 2020, 33, 108274.	2.9	152
111	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. <i>Journal of Experimental Medicine</i> , 2017, 214, 2573-2590.	4.2	151
112	Crystal structure of Sar1-GDP at 1.7 Å resolution and the role of the NH2 terminus in ER export. <i>Journal of Cell Biology</i> , 2001, 155, 937-948.	2.3	149
113	Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 11440-11445.	3.3	149
114	Applications of the streak seeding technique in protein crystallization. <i>Journal of Crystal Growth</i> , 1991, 110, 270-282.	0.7	147
115	Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. <i>Nature Communications</i> , 2016, 7, 12041.	5.8	146
116	An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability. <i>Nature Microbiology</i> , 2017, 2, 16199.	5.9	144
117	A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 363-370.	3.6	141
118	Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site. <i>Journal of Virology</i> , 2013, 87, 12471-12480.	1.5	139
119	Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits. <i>Retrovirology</i> , 2014, 11, 41.	0.9	139
120	Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. <i>Immunity</i> , 2016, 44, 1215-1226.	6.6	138
121	Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C. <i>PLoS Pathogens</i> , 2016, 12, e1005864.	2.1	138
122	Broadly neutralizing antibodies against influenza viruses. <i>Antiviral Research</i> , 2013, 98, 476-483.	1.9	136
123	The challenge of protein structure determination—lessons from structural genomics. <i>Protein Science</i> , 2007, 16, 2472-2482.	3.1	135
124	Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9499-9504.	3.3	135
125	Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1458-1463.	3.3	135
126	Structural Constraints Determine the Glycosylation of HIV-1 Envelope Trimers. <i>Cell Reports</i> , 2015, 11, 1604-1613.	2.9	135

#	ARTICLE	IF	CITATIONS
127	Potent peptidic fusion inhibitors of influenza virus. <i>Science</i> , 2017, 358, 496-502.	6.0	135
128	Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability. <i>Nature Communications</i> , 2016, 7, 12040.	5.8	134
129	Preferential Recognition of Avian-Like Receptors in Human Influenza A H7N9 Viruses. <i>Science</i> , 2013, 342, 1230-1235.	6.0	133
130	A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus. <i>Journal of Molecular Biology</i> , 2017, 429, 2694-2709.	2.0	133
131	Antibody potency relates to the ability to recognize the closed, pre-fusion form of HIV Env. <i>Nature Communications</i> , 2015, 6, 6144.	5.8	130
132	A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. <i>Immunity</i> , 2016, 45, 31-45.	6.6	129
133	Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11947-11952.	3.3	127
134	HMGB1 Activates Proinflammatory Signaling via TLR5 Leading to Allodynia. <i>Cell Reports</i> , 2016, 17, 1128-1140.	2.9	125
135	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2022, 14, eabi9215.	5.8	123
136	Structural Basis of Enhanced Binding of Extended and Helically Constrained Peptide Epitopes of the Broadly Neutralizing HIV-1 Antibody 4E10. <i>Journal of Molecular Biology</i> , 2007, 365, 1533-1544.	2.0	121
137	Structural basis for antibody recognition of the NANP repeats in <i>Plasmodium falciparum</i> circumsporozoite protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10438-E10445.	3.3	116
138	Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. <i>Nature Communications</i> , 2019, 10, 2355.	5.8	116
139	Structure and Immune Recognition of the HIV Glycan Shield. <i>Annual Review of Biophysics</i> , 2018, 47, 499-523.	4.5	115
140	Structure of a Classical Broadly Neutralizing Stem Antibody in Complex with a Pandemic H2 Influenza Virus Hemagglutinin. <i>Journal of Virology</i> , 2013, 87, 7149-7154.	1.5	114
141	Structural Characterization of an Early Fusion Intermediate of Influenza Virus Hemagglutinin. <i>Journal of Virology</i> , 2011, 85, 5172-5182.	1.5	113
142	The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	113
143	A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120. <i>Journal of Virology</i> , 2008, 82, 6359-6368.	1.5	112
144	Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. <i>PLoS Pathogens</i> , 2018, 14, e1006913.	2.1	111

#	ARTICLE	IF	CITATIONS
145	Broadly neutralizing antibodies target the coronavirus fusion peptide. <i>Science</i> , 2022, 377, 728-735.	6.0	111
146	Characterization of a Broadly Neutralizing Monoclonal Antibody That Targets the Fusion Domain of Group 2 Influenza A Virus Hemagglutinin. <i>Journal of Virology</i> , 2014, 88, 13580-13592.	1.5	110
147	CD4-Induced Activation in a Soluble HIV-1 Env Trimer. <i>Structure</i> , 2014, 22, 974-984.	1.6	108
148	Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site. <i>Nature Biotechnology</i> , 2017, 35, 667-671.	9.4	108
149	Genetically encoding phosphotyrosine and its nonhydrolyzable analog in bacteria. <i>Nature Chemical Biology</i> , 2017, 13, 845-849.	3.9	105
150	Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. <i>PLoS Pathogens</i> , 2016, 12, e1005815.	2.1	104
151	Antibody 27F3 Broadly Targets Influenza A Group 1 and 2 Hemagglutinins through a Further Variation in VH1-69 Antibody Orientation on the HA Stem. <i>Cell Reports</i> , 2017, 20, 2935-2943.	2.9	103
152	Comprehensive Antigenic Map of a Cleaved Soluble HIV-1 Envelope Trimer. <i>PLoS Pathogens</i> , 2015, 11, e1004767.	2.1	100
153	The JCSG high-throughput structural biology pipeline. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2010, 66, 1137-1142.	0.7	99
154	Analytical and production seeding techniques. <i>Methods</i> , 1990, 1, 38-49.	1.9	98
155	A small-molecule fusion inhibitor of influenza virus is orally active in mice. <i>Science</i> , 2019, 363, .	6.0	98
156	Glycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein. <i>Immunity</i> , 2017, 46, 792-803.e3.	6.6	96
157	Insights into the trimeric HIV-1 envelope glycoprotein structure. <i>Trends in Biochemical Sciences</i> , 2015, 40, 101-107.	3.7	95
158	A Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing Antibodies. <i>Journal of Virology</i> , 2009, 83, 8451-8462.	1.5	92
159	VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design. <i>Current Opinion in Virology</i> , 2019, 34, 149-159.	2.6	92
160	Structure, Receptor Binding, and Antigenicity of Influenza Virus Hemagglutinins from the 1957 H2N2 Pandemic. <i>Journal of Virology</i> , 2010, 84, 1715-1721.	1.5	90
161	HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage. <i>Immunity</i> , 2017, 47, 990-1003.e9.	6.6	90
162	Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers. <i>Journal of Virology</i> , 2015, 89, 12189-12210.	1.5	88

#	ARTICLE	IF	CITATIONS
163	Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike. <i>Nature Communications</i> , 2015, 6, 8167.	5.8	87
164	Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10. <i>Immunity</i> , 2016, 44, 21-31.	6.6	87
165	A Fluorogenic Aryl Fluorosulfate for Intraorganellar Transthyretin Imaging in Living Cells and in <i>Caenorhabditis elegans</i> . <i>Journal of the American Chemical Society</i> , 2015, 137, 7404-7414.	6.6	86
166	A Structurally Distinct Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union. <i>Science</i> , 2014, 343, 656-661.	6.0	85
167	Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. <i>Immunity</i> , 2016, 44, 939-950.	6.6	85
168	Structural insights into key sites of vulnerability on HIV Env and influenza HA. <i>Immunological Reviews</i> , 2012, 250, 180-198.	2.8	84
169	Structural Characterization of Viral Epitopes Recognized by Broadly Cross-Reactive Antibodies. <i>Current Topics in Microbiology and Immunology</i> , 2014, 386, 323-341.	0.7	83
170	Three mutations switch H7N9 influenza to human-type receptor specificity. <i>PLoS Pathogens</i> , 2017, 13, e1006390.	2.1	83
171	Structural insights into the design of novel anti-influenza therapies. <i>Nature Structural and Molecular Biology</i> , 2018, 25, 115-121.	3.6	81
172	Influenza Human Monoclonal Antibody 1F1 Interacts with Three Major Antigenic Sites and Residues Mediating Human Receptor Specificity in H1N1 Viruses. <i>PLoS Pathogens</i> , 2012, 8, e1003067.	2.1	80
173	Two Classes of Broadly Neutralizing Antibodies within a Single Lineage Directed to the High-Mannose Patch of HIV Envelope. <i>Journal of Virology</i> , 2015, 89, 1105-1118.	1.5	80
174	Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates. <i>Science Advances</i> , 2021, 7, .	4.7	80
175	Structure of Hepatitis C Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33. <i>Journal of Virology</i> , 2012, 86, 13085-13088.	1.5	79
176	Influenza Hemagglutinin Structures and Antibody Recognition. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a038778.	2.9	79
177	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	5.8	79
178	A Distinct Type of Pilus from the Human Microbiome. <i>Cell</i> , 2016, 165, 690-703.	13.5	78
179	Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12768-12773.	3.3	78
180	N-Glycolylneuraminic Acid as a Receptor for Influenza A Viruses. <i>Cell Reports</i> , 2019, 27, 3284-3294.e6.	2.9	78

#	ARTICLE	IF	CITATIONS
181	Genetic and structural insights into broad neutralization of hepatitis C virus by human V_H 1-69 antibodies. <i>Science Advances</i> , 2019, 5, eaav1882.	4.7	77
182	Influences on Trimerization and Aggregation of Soluble, Cleaved HIV-1 SOSIP Envelope Glycoprotein. <i>Journal of Virology</i> , 2013, 87, 9873-9885.	1.5	76
183	cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate. <i>Biotechnology and Bioengineering</i> , 2018, 115, 885-899.	1.7	75
184	HIV-1 vaccine design through minimizing envelope metastability. <i>Science Advances</i> , 2018, 4, eaau6769.	4.7	75
185	Structural Basis of Murein Peptide Specificity of a $\hat{\text{I}}^3$ -D-Glutamyl-L-Diamino Acid Endopeptidase. <i>Structure</i> , 2009, 17, 303-313.	1.6	73
186	Structural Characterization of Cleaved, Soluble HIV-1 Envelope Glycoprotein Trimers. <i>Journal of Virology</i> , 2013, 87, 9865-9872.	1.5	71
187	Cryo-EM structure of <i>P. falciparum</i> circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. <i>Science Advances</i> , 2018, 4, eaau8529.	4.7	70
188	Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies. <i>Nature Structural and Molecular Biology</i> , 2014, 21, 1058-1067.	3.6	69
189	Complete epitopes for vaccine design derived from a crystal structure of the broadly neutralizing antibodies PGT128 and 8ANC195 in complex with an HIV-1 Env trimer. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2015, 71, 2099-2108.	2.5	69
190	Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. <i>Scientific Reports</i> , 2015, 5, 12501.	1.6	68
191	Structure of 2G12 Fab in Complex with Soluble and Fully Glycosylated HIV-1 Env by Negative-Stain Single-Particle Electron Microscopy. <i>Journal of Virology</i> , 2014, 88, 10177-10188.	1.5	67
192	A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. <i>Nature Communications</i> , 2018, 9, 2669.	5.8	67
193	Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens. <i>Journal of Infectious Diseases</i> , 2019, 219, S38-S45.	1.9	67
194	Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes. <i>Journal of Virology</i> , 2019, 93, .	1.5	66
195	Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis. <i>PLoS Pathogens</i> , 2017, 13, e1006735.	2.1	66
196	The Carbohydrate Epitope of the Neutralizing Anti-HIV-1 Antibody 2G12. <i>Advances in Experimental Medicine and Biology</i> , 2003, 535, 205-218.	0.8	65
197	Structure of the $\hat{\text{I}}^3$ -D-glutamyl-L-diamino acid endopeptidase YkfC from <i>Bacillus cereus</i> in complex with L-Ala- $\hat{\text{I}}^3$ -D-Glu: insights into substrate recognition by NlpC/P60 cysteine peptidases. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2010, 66, 1354-1364.	0.7	64
198	Alternative Recognition of the Conserved Stem Epitope in Influenza A Virus Hemagglutinin by a V_H 3-30-Encoded Heterosubtypic Antibody. <i>Journal of Virology</i> , 2014, 88, 7083-7092.	1.5	62

#	ARTICLE	IF	CITATIONS
199	H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. <i>Journal of Clinical Investigation</i> , 2016, 126, 1482-1494.	3.9	62
200	Hemagglutinin Receptor Specificity and Structural Analyses of Respiratory Droplet-Transmissible H5N1 Viruses. <i>Journal of Virology</i> , 2014, 88, 768-773.	1.5	61
201	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. <i>PLoS Pathogens</i> , 2020, 16, e1008753.	2.1	61
202	HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies. <i>Cell Reports</i> , 2020, 31, 107583.	2.9	60
203	SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies. <i>Science</i> , 2022, 375, 782-787.	6.0	60
204	Diversity of Functionally Permissive Sequences in the Receptor-Binding Site of Influenza Hemagglutinin. <i>Cell Host and Microbe</i> , 2017, 21, 742-753.e8.	5.1	59
205	Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. <i>Cell Reports</i> , 2017, 21, 222-235.	2.9	58
206	A complex epistatic network limits the mutational reversibility in the influenza hemagglutinin receptor-binding site. <i>Nature Communications</i> , 2018, 9, 1264.	5.8	58
207	Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. <i>PLoS Pathogens</i> , 2017, 13, e1006212.	2.1	58
208	Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers. <i>Journal of Virology</i> , 2017, 91, .	1.5	57
209	Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits. <i>Journal of Virology</i> , 2020, 94, .	1.5	57
210	Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5335-E5342.	3.3	56
211	The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. <i>Frontiers in Immunology</i> , 2018, 9, 1315.	2.2	56
212	In vitro evolution of an influenza broadly neutralizing antibody is modulated by hemagglutinin receptor specificity. <i>Nature Communications</i> , 2017, 8, 15371.	5.8	55
213	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. <i>PLoS Pathogens</i> , 2020, 16, e1009089.	2.1	55
214	Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. <i>Current Opinion in Virology</i> , 2015, 11, 148-157.	2.6	54
215	A Human-Infecting H10N8 Influenza Virus Retains a Strong Preference for Avian-type Receptors. <i>Cell Host and Microbe</i> , 2015, 17, 377-384.	5.1	54
216	Conservation and diversity in the ultralong third heavy-chain complementarity-determining region of bovine antibodies. <i>Science Immunology</i> , 2016, 1, .	5.6	52

#	ARTICLE	IF	CITATIONS
217	Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design. <i>Cell Reports</i> , 2018, 23, 3249-3261.	2.9	52
218	Stabilization of amyloidogenic immunoglobulin light chains by small molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 8360-8369.	3.3	52
219	A Unique and Conserved Neutralization Epitope in H5N1 Influenza Viruses Identified by an Antibody against the A/Goose/Guangdong/1/96 Hemagglutinin. <i>Journal of Virology</i> , 2013, 87, 12619-12635.	1.5	51
220	Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. <i>Cell Host and Microbe</i> , 2019, 26, 729-738.e4.	5.1	51
221	Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses. <i>Science</i> , 2020, 368, 1335-1340.	6.0	51
222	Structure of a cleavage-independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer. <i>Nature Communications</i> , 2018, 9, 1956.	5.8	50
223	A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. <i>PLoS Pathogens</i> , 2016, 12, e1005409.	2.1	49
224	Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. <i>Cell Host and Microbe</i> , 2019, 26, 715-728.e8.	5.1	49
225	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021, 29, 806-818.e6.	5.1	49
226	Structure-based optimization and synthesis of antiviral drug Arbidol analogues with significantly improved affinity to influenza hemagglutinin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3744-3748.	1.0	48
227	Monoglucosylated glycans in the secreted human complement component C3: implications for protein biosynthesis and structure. <i>FEBS Letters</i> , 2004, 566, 270-274.	1.3	47
228	Variable Lymphocyte Receptor Recognition of the Immunodominant Glycoprotein of <i>Bacillus anthracis</i> Spores. <i>Structure</i> , 2012, 20, 479-486.	1.6	47
229	Stable 293ÅT and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies. <i>Retrovirology</i> , 2014, 11, 33.	0.9	46
230	Insights into Substrate Specificity of NlpC/P60 Cell Wall Hydrolases Containing Bacterial SH3 Domains. <i>MBio</i> , 2015, 6, e02327-14.	1.8	46
231	Bacterial glycosyltransferase-mediated cell-surface chemoenzymatic glycan modification. <i>Nature Communications</i> , 2019, 10, 1799.	5.8	46
232	Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. <i>Cell Reports</i> , 2021, 35, 109173.	2.9	46
233	Preventing an Antigenically Disruptive Mutation in Egg-Based H3N2 Seasonal Influenza Vaccines by Mutational Incompatibility. <i>Cell Host and Microbe</i> , 2019, 25, 836-844.e5.	5.1	45
234	Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526. <i>Journal of Molecular Biology</i> , 2015, 427, 2617-2628.	2.0	44

#	ARTICLE	IF	CITATIONS
235	Structure and Receptor Binding of the Hemagglutinin from a Human H6N1 Influenza Virus. <i>Cell Host and Microbe</i> , 2015, 17, 369-376.	5.1	44
236	A single mutation in Taiwanese H6N1 influenza hemagglutinin switches binding to human α 2 type receptors. <i>EMBO Molecular Medicine</i> , 2017, 9, 1314-1325.	3.3	44
237	An MPER antibody neutralizes HIV-1 using germline features shared among donors. <i>Nature Communications</i> , 2019, 10, 5389.	5.8	44
238	Proof of concept for rational design of hepatitis C virus E2 core nanoparticle vaccines. <i>Science Advances</i> , 2020, 6, eaaz6225.	4.7	44
239	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. <i>Nature Communications</i> , 2021, 12, 3815.	5.8	44
240	A large-scale systematic survey reveals recurring molecular features of public antibody responses to SARS-CoV-2. <i>Immunity</i> , 2022, 55, 1105-1117.e4.	6.6	44
241	Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 4666-4671.	3.3	43
242	Immunological memory to hyperphosphorylated tau in asymptomatic individuals. <i>Acta Neuropathologica</i> , 2017, 133, 767-783.	3.9	43
243	Innovations in structure-based antigen design and immune monitoring for next generation vaccines. <i>Current Opinion in Immunology</i> , 2020, 65, 50-56.	2.4	43
244	Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10206-10217.	2.9	42
245	Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2019, 25, 873-883.e5.	5.1	42
246	Structural Insights into the Lipid A Transport Pathway in MsbA. <i>Structure</i> , 2019, 27, 1114-1123.e3.	1.6	41
247	Stabilizing the C _H 2 Domain of an Antibody by Engineering in an Enhanced Aromatic Sequon. <i>ACS Chemical Biology</i> , 2016, 11, 1852-1861.	1.6	40
248	Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2018, 293, 1688-1701.	1.6	40
249	Major antigenic site B of human influenza H3N2 viruses has an evolving local fitness landscape. <i>Nature Communications</i> , 2020, 11, 1233.	5.8	40
250	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <i>Nature Immunology</i> , 2022, 23, 960-970.	7.0	39
251	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021, 12, 6097.	5.8	38
252	A New Functional Domain of Guanine Nucleotide Dissociation Inhibitor ($\hat{\pm}$ -GDI) Involved in Rab Recycling. <i>Traffic</i> , 2000, 1, 270-281.	1.3	37

#	ARTICLE	IF	CITATIONS
253	Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. <i>PLoS Biology</i> , 2019, 17, e3000139.	2.6	37
254	UHM-ULM interactions in the RBM39-U2AF65 splicing-factor complex. <i>Acta Crystallographica Section D: Structural Biology</i> , 2016, 72, 497-511.	1.1	36
255	The Unusual Genetics and Biochemistry of Bovine Immunoglobulins. <i>Advances in Immunology</i> , 2018, 137, 135-164.	1.1	36
256	Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors. <i>Chemical Communications</i> , 2013, 49, 9188.	2.2	35
257	The 150-Loop Restricts the Host Specificity of Human H10N8 Influenza Virus. <i>Cell Reports</i> , 2017, 19, 235-245.	2.9	35
258	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. <i>Cell Reports</i> , 2019, 27, 2426-2441.e6.	2.9	35
259	Structural Biology of Influenza Hemagglutinin: An Amaranthine Adventure. <i>Viruses</i> , 2020, 12, 1053.	1.5	35
260	A broad and potent neutralization epitope in SARS-related coronaviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	34
261	Bacterially derived synthetic mimetics of mammalian oligomannose prime antibody responses that neutralize HIV infectivity. <i>Nature Communications</i> , 2017, 8, 1601.	5.8	33
262	Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities. <i>ACS Central Science</i> , 2019, 5, 237-249.	5.3	33
263	Design and Structure of an Engineered Disulfide-Stabilized Influenza Virus Hemagglutinin Trimer. <i>Journal of Virology</i> , 2015, 89, 7417-7420.	1.5	32
264	Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene. <i>Cell Host and Microbe</i> , 2018, 24, 569-578.e4.	5.1	32
265	Antibody Structure. <i>Microbiology Spectrum</i> , 2014, 2, .	1.2	31
266	Selection of nanobodies with broad neutralizing potential against primary HIV-1 strains using soluble subtype C gp140 envelope trimers. <i>Scientific Reports</i> , 2017, 7, 8390.	1.6	31
267	Structural basis of broad HIV neutralization by a vaccine-induced cow antibody. <i>Science Advances</i> , 2020, 6, eaba0468.	4.7	31
268	Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. <i>Journal of Clinical Investigation</i> , 2015, 125, 2523-2531.	3.9	31
269	Capturing the inherent structural dynamics of the HIV-1 envelope glycoprotein fusion peptide. <i>Nature Communications</i> , 2019, 10, 763.	5.8	30
270	Structure and mechanism of monoclonal antibody binding to the junctional epitope of <i>Plasmodium falciparum</i> circumsporozoite protein. <i>PLoS Pathogens</i> , 2020, 16, e1008373.	2.1	30

#	ARTICLE	IF	CITATIONS
271	Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against <i>P. falciparum</i> . <i>Nature Communications</i> , 2021, 12, 1063.	5.8	30
272	Neutralizing Antibody Induction by HIV-1 Envelope Glycoprotein SOSIP Trimers on Iron Oxide Nanoparticles May Be Impaired by Mannose Binding Lectin. <i>Journal of Virology</i> , 2020, 94, .	1.5	29
273	Diverse Antibody Responses to Conserved Structural Motifs in <i>Plasmodium falciparum</i> Circumsporozoite Protein. <i>Journal of Molecular Biology</i> , 2020, 432, 1048-1063.	2.0	28
274	Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose. <i>Glycobiology</i> , 2015, 25, 412-419.	1.3	27
275	Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. <i>Journal of Virology</i> , 2017, 91, .	1.5	27
276	Structural Insights into VLR Fine Specificity for Blood Group Carbohydrates. <i>Structure</i> , 2017, 25, 1667-1678.e4.	1.6	27
277	Defining the Structural Basis for Allosteric Product Release from <i>E. coli</i> Dihydrofolate Reductase Using NMR Relaxation Dispersion. <i>Journal of the American Chemical Society</i> , 2017, 139, 11233-11240.	6.6	27
278	Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2120976119.	3.3	27
279	An alternate conformation of HCV E2 neutralizing face as an additional vaccine target. <i>Science Advances</i> , 2020, 6, eabb5642.	4.7	26
280	Structures of a Bifunctional Cell Wall Hydrolase CwlT Containing a Novel Bacterial Lysozyme and an NlpC/P60 dl-Endopeptidase. <i>Journal of Molecular Biology</i> , 2014, 426, 169-184.	2.0	25
281	Soluble human TLR2 ectodomain binds diacylglycerol from microbial lipopeptides and glycolipids. <i>Innate Immunity</i> , 2015, 21, 175-193.	1.1	25
282	A small-molecule fragment that emulates binding of receptor and broadly neutralizing antibodies to influenza A hemagglutinin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 4240-4245.	3.3	25
283	An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18431-18438.	3.3	25
284	Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines. <i>Nature Communications</i> , 2021, 12, 2633.	5.8	25
285	X-Ray Crystallographic Studies of Antibody-Peptide Complexes. <i>ImmunoMethods</i> , 1993, 3, 211-221.	0.8	24
286	Integrity of Glycosylation Processing of a Glycan-Depleted Trimeric HIV-1 Immunogen Targeting Key B-Cell Lineages. <i>Journal of Proteome Research</i> , 2018, 17, 987-999.	1.8	23
287	Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1597-1602.	3.3	23
288	A cross-neutralizing antibody between HIV-1 and influenza virus. <i>PLoS Pathogens</i> , 2021, 17, e1009407.	2.1	23

#	ARTICLE	IF	CITATIONS
289	Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins. <i>Immunity</i> , 2021, 54, 781-796.e4.	6.6	23
290	Protective neutralizing epitopes in SARS-CoV-2. <i>Immunological Reviews</i> , 2022, 310, 76-92.	2.8	23
291	Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans. <i>Cell Reports</i> , 2019, 29, 4460-4470.e8.	2.9	22
292	A high-affinity antibody against the CSP N-terminal domain lacks inhibitory activity. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	21
293	Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. <i>Cell Reports</i> , 2021, 35, 109109.	2.9	21
294	Functional human IgA targets a conserved site on malaria sporozoites. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	21
295	A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. <i>MBio</i> , 2021, 12, e0224121.	1.8	21
296	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. <i>ACS Central Science</i> , 2021, 7, 1863-1873.	5.3	20
297	A V _H -1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. <i>Science Advances</i> , 2020, 6, .	4.7	19
298	Engineering protein for X-ray crystallography: The murine major histocompatibility complex class II molecule I-A ^d . <i>Protein Science</i> , 1998, 7, 413-418.	3.1	18
299	Structural Basis for a Switch in Receptor Binding Specificity of Two H5N1 Hemagglutinin Mutants. <i>Cell Reports</i> , 2015, 13, 1683-1691.	2.9	18
300	Crystal structure of the post-fusion core of the Human coronavirus 229E spike protein at 1.86-Å resolution. <i>Acta Crystallographica Section D: Structural Biology</i> , 2018, 74, 841-851.	1.1	18
301	Structural basis for cooperative regulation of KIX-mediated transcription pathways by the HTLV-1 HBZ activation domain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10040-10045.	3.3	18
302	Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers. <i>Journal of Biological Chemistry</i> , 2019, 294, 5616-5631.	1.6	16
303	Convergent Evolution in Breadth of Two VH6-1-Encoded Influenza Antibody Clonotypes from a Single Donor. <i>Cell Host and Microbe</i> , 2020, 28, 434-444.e4.	5.1	16
304	Discovery of Potent Coumarin-Based Kinetic Stabilizers of Amyloidogenic Immunoglobulin Light Chains Using Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6273-6299.	2.9	16
305	Crystal Structure and Activity Studies of the C11 Cysteine Peptidase from <i>Parabacteroides merdae</i> in the Human Gut Microbiome. <i>Journal of Biological Chemistry</i> , 2016, 291, 9482-9491.	1.6	15
306	A common antigenic motif recognized by naturally occurring human VH5 ¹ /VL4 ¹ anti-tau antibodies with distinct functionalities. <i>Acta Neuropathologica Communications</i> , 2018, 6, 43.	2.4	15

#	ARTICLE	IF	CITATIONS
307	Vaccine innovations for emerging infectious diseases—a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2020, 1462, 14-26.	1.8	15
308	Structural basis for the stabilization of amyloidogenic immunoglobulin light chains by hydantoins. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127356.	1.0	15
309	50 Years of structural immunology. <i>Journal of Biological Chemistry</i> , 2021, 296, 100745.	1.6	15
310	Immunogenetic and structural analysis of a class of HCV broadly neutralizing antibodies and their precursors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 7569-7574.	3.3	14
311	Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago. <i>Advanced Science</i> , 2022, 9, e2102181.	5.6	14
312	<i>N</i> -Glycolylneuraminic Acid Binding of Avian and Equine H7 Influenza A Viruses. <i>Journal of Virology</i> , 2022, 96, jvi0212021.	1.5	14
313	A novel CSP C-terminal epitope targeted by an antibody with protective activity against <i>Plasmodium falciparum</i> . <i>PLoS Pathogens</i> , 2022, 18, e1010409.	2.1	14
314	Structural basis for differential recognition of phosphohistidine-containing peptides by 1-pHis and 3-pHis monoclonal antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	13
315	Novel lamprey antibody recognizes terminal sulfated galactose epitopes on mammalian glycoproteins. <i>Communications Biology</i> , 2021, 4, 674.	2.0	13
316	Superimmunity by pan-sarbecovirus nanobodies. <i>Cell Reports</i> , 2022, 39, 111004.	2.9	13
317	Unique Structural Features of Influenza Virus H15 Hemagglutinin. <i>Journal of Virology</i> , 2017, 91, .	1.5	12
318	VLR Recognition of TLR5 Expands the Molecular Characterization of Protein Antigen Binding by Non-Ig-based Antibodies. <i>Journal of Molecular Biology</i> , 2018, 430, 1350-1367.	2.0	12
319	Selection of a picomolar antibody that targets CXCR2-mediated neutrophil activation and alleviates EAE symptoms. <i>Nature Communications</i> , 2021, 12, 2547.	5.8	11
320	Structure-Guided Functional Characterization of DUF1460 Reveals a Highly Specific NlpC/P60 Amidase Family. <i>Structure</i> , 2014, 22, 1799-1809.	1.6	10
321	Dlx5 Homeodomain:DNA Complex: Structure, Binding and Effect of Mutations Related to Split Hand and Foot Malformation Syndrome. <i>Journal of Molecular Biology</i> , 2016, 428, 1130-1141.	2.0	10
322	NMR Based SARS-CoV-2 Antibody Screening. <i>Journal of the American Chemical Society</i> , 2021, 143, 7930-7934.	6.6	10
323	Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	10
324	A General Method for Insertion of Functional Proteins within Proteins via Combinatorial Selection of Permissive Junctions. <i>Chemistry and Biology</i> , 2015, 22, 1134-1143.	6.2	9

#	ARTICLE	IF	CITATIONS
325	Structural Basis for Recognition of a Unique Epitope by a Human Anti-tau Antibody. <i>Structure</i> , 2018, 26, 1626-1634.e4.	1.6	9
326	The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans. <i>ACS Chemical Biology</i> , 2020, 15, 789-798.	1.6	9
327	Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3441-3449.	1.0	8
328	Structure and Function of the DUF2233 Domain in Bacteria and in the Human Mannose 6-Phosphate Uncovering Enzyme. <i>Journal of Biological Chemistry</i> , 2013, 288, 16789-16799.	1.6	7
329	A Dynamic Switch in Inactive p38 ^β Leads to an Excited State on the Pathway to an Active Kinase. <i>Biochemistry</i> , 2019, 58, 5160-5172.	1.2	7
330	Inhibitory antibodies identify unique sites of therapeutic vulnerability in rhinovirus and other enteroviruses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 13499-13508.	3.3	7
331	Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice. <i>European Journal of Immunology</i> , 2021, 51, 2296-2305.	1.6	7
332	Structural Insights into the Recognition of Phosphopeptide by the FHA Domain of Kanadaptin. <i>PLoS ONE</i> , 2014, 9, e107309.	1.1	6
333	HIV's Achilles' Heel. <i>Scientific American</i> , 2016, 315, 50-55.	1.0	6
334	Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles. <i>MBio</i> , 2021, 12, e0042921.	1.8	6
335	Antigenic imprinting in SARS-CoV-2. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	6
336	Structure of the apo anti-influenza CH65 Fab. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2015, 71, 145-148.	0.4	5
337	Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 60, 128571.	1.0	5
338	Structures of single-layer β-sheet proteins evolved from β-hairpin repeats. <i>Protein Science</i> , 2019, 28, 1676-1689.	3.1	4
339	Toward a Carbohydrate-Based HIV-1 Vaccine. <i>ACS Symposium Series</i> , 2006, , 161-185.	0.5	3
340	Crystal structure of an anti-idiotypic variable lymphocyte receptor. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2017, 73, 682-687.	0.4	3
341	Dynamic Local Polymorphisms in the Cbx1 Homeodomain Induced by DNA Binding. <i>Structure</i> , 2016, 24, 1372-1379.	1.6	2
342	Crystal Structure of a Two-Subunit TrkA Octameric Gating Ring Assembly. <i>PLoS ONE</i> , 2015, 10, e0122512.	1.1	2

#	ARTICLE	IF	CITATIONS
343	Dynamics of B-Cell Repertoires and Emergence of Cross-Reactive Responses in COVID-19 Patients with Different Disease Severity. SSRN Electronic Journal, 0, , .	0.4	2
344	Neutralizing Antibody Response to Sarbecovirus Is Delayed in Sequential Heterologous Immunization. Viruses, 2022, 14, 1382.	1.5	2
345	Antibody Structure. , 0, , 49-62.		1
346	Structural and Biochemical Characterization of Cysteinylation in Broadly Neutralizing Antibodies to HIV-1. Journal of Molecular Biology, 2021, 433, 167303.	2.0	1
347	STRUCTURAL BASIS FOR HOST/COMMENSAL-MICROBE INTERACTIONS IN THE HUMAN DISTAL GUT MICROBIOME. , 2014, , .		0
348	HIV ENVELOPE AND INFLUENZA HEMAGGLUTININ FUSION GLYCOPROTEINS AND THE QUEST FOR A UNIVERSAL VACCINE. , 2014, , .		0
349	Novel Rigid Glycomimetics to Inhibit Influenza Infection. FASEB Journal, 2019, 33, .	0.2	0
350	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
351	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
352	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0
353	Mapping the immunogenic landscape of near-native HIV-1 envelope trimers in non-human primates. , 2020, 16, e1008753.		0